Open-label, exploratory, pharmacodynamic (PD) dose-finding study of intravenous RO5323441 in patients with metastatic treatment-refractory colorectal and ovarian cancer

Trial Profile

Open-label, exploratory, pharmacodynamic (PD) dose-finding study of intravenous RO5323441 in patients with metastatic treatment-refractory colorectal and ovarian cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs THR 317 (Primary)
  • Indications Colorectal cancer; Ovarian cancer
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 15 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jan 2011 Planned End Date changed from 1 Nov 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 15 Jul 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health)(NCT01148758).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top